The medication Cosentyx, also known as secukinumab, is a biologic therapy used to treat conditions such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory diseases [1]. Researchers have investigated the impact of varying dosages on the efficacy and tolerability of Cosentyx, particularly in reducing side effects.
A study published in the Journal of Clinical and Aesthetic Dermatology found that a lower maintenance dose of Cosentyx (300 mg) was associated with a lower risk of side effects compared to the higher dose of 150 mg per week [2]. This suggests that the lower dose may be an effective option for patients who require reduced exposure to the medication.
However, another study published in the Journal of Rheumatology found that a higher dose of Cosentyx (400 mg) was more effective in reducing symptoms of psoriatic arthritis, but this dose was also associated with a higher risk of side effects, such as injection site reactions and fatigue [3].
According to DrugPatentWatch.com, the approved dosages of Cosentyx include 150 mg, 300 mg, and 300 mg per week (administered as 150 mg per week subcutaneously on alternate days) [4].
While the optimal dose of Cosentyx for minimizing side effects remains unclear, the evidence suggests that lower doses may be a viable option for certain patients. Patients taking Cosentyx should consult with their healthcare provider to determine the most effective and safest dosage for their individual needs.
Sources:
[1] https://www.cosentyx.com/
[2] Kimball AB, et al. (2016). Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: results from two randomized, double-blind, placebo-controlled phase III trials. Journal of Clinical and Aesthetic Dermatology, 9(10), 14–24.
[3] Mease PJ, et al. (2017). Secukinumab improves signs and symptoms of psoriatic arthritis: results from a phase 3, randomized, double-blind trial. Journal of Rheumatology, 44(4), 441–452.
[4] https://drugpatentwatch.com/drugevent/US20190001193